HRP20211049T1 - Identifikacija i izolacija humanog otičkog progenitora - Google Patents
Identifikacija i izolacija humanog otičkog progenitora Download PDFInfo
- Publication number
- HRP20211049T1 HRP20211049T1 HRP20211049TT HRP20211049T HRP20211049T1 HR P20211049 T1 HRP20211049 T1 HR P20211049T1 HR P20211049T T HRP20211049T T HR P20211049TT HR P20211049 T HRP20211049 T HR P20211049T HR P20211049 T1 HRP20211049 T1 HR P20211049T1
- Authority
- HR
- Croatia
- Prior art keywords
- cell
- cells
- bind
- binding members
- otic progenitor
- Prior art date
Links
- 238000002955 isolation Methods 0.000 title 1
- 210000004027 cell Anatomy 0.000 claims 48
- 238000000034 method Methods 0.000 claims 19
- 210000000130 stem cell Anatomy 0.000 claims 15
- 239000002771 cell marker Substances 0.000 claims 7
- 238000000338 in vitro Methods 0.000 claims 5
- 238000001514 detection method Methods 0.000 claims 3
- 238000001943 fluorescence-activated cell sorting Methods 0.000 claims 2
- 210000004263 induced pluripotent stem cell Anatomy 0.000 claims 2
- 238000002826 magnetic-activated cell sorting Methods 0.000 claims 2
- 239000003550 marker Substances 0.000 claims 2
- 210000001778 pluripotent stem cell Anatomy 0.000 claims 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 1
- 230000024245 cell differentiation Effects 0.000 claims 1
- 230000032459 dedifferentiation Effects 0.000 claims 1
- 230000004069 differentiation Effects 0.000 claims 1
- 210000003027 ear inner Anatomy 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000008672 reprogramming Effects 0.000 claims 1
- 230000001720 vestibular Effects 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
- C07K16/3084—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated gangliosides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0618—Cells of the nervous system
- C12N5/0623—Stem cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/745—Assays involving non-enzymic blood coagulation factors
- G01N2333/7452—Thrombomodulin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/916—Hydrolases (3) acting on ester bonds (3.1), e.g. phosphatases (3.1.3), phospholipases C or phospholipases D (3.1.4)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Neurosurgery (AREA)
- Developmental Biology & Embryology (AREA)
- Neurology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines Containing Plant Substances (AREA)
- Materials For Medical Uses (AREA)
- Peptides Or Proteins (AREA)
Claims (15)
1. In vitro postupak identificiranja humanih otičkih progenitorskih stanica u mješovitoj populaciji stanica koji sadrži određivanje da li stanica ima najmanje dva markera stanične površine odabrana od SSEA1, GD3, TRA-2-49, SSEA4, GD2 i CD141.
2. Postupak u skladu sa patentnim zahtjevom 1, naznačen time što:
a) stanični markeri SSEA1, GD3, TRA-2-49, SSEA4, i GD2 su pozitivni stanični markeri; i/ili
b) stanični marker CD141 je negativni stanični marker.
3. Postupak u skladu sa patentnim zahtjevom 1 ili 2, naznačen time što:
(a) najmanje dva pozitivna stanična markera se upotrebljavaju u kombinaciji za identifikaciju humanih otičkih progenitora; ili
(b) najmanje tri, četiri ili pet pozitivnih staničnih markera se upotrebljava u kombinaciji za identifikaciju humanih otičkih progenitora; ili
(c) pozitivan stanični marker, ili najmanje dva pozitivna stanična markera se upotrebljavaju u kombinaciji sa negativnim staničnim markerom CD141.
4. Postupak u skladu sa bilo kojim od prethodnih patentnih zahtjeva, naznačen time što se mješovita populacija stanica osigurava iz, ili tokom, in vitro protokola diferencijacije pluripotentnih matičnih stanica, izborno pri čemu su pluripotentne matične stanice inducirane pluripotentne matične stanice (iPSC); ili
pri čemu se mješovita populacija stanica osigurava iz, ili tokom, procedura dediferenciranja, transdiferenciranja ili direktnog reprogramiranja u humane otičke stanične loze; ili
pri čemu se mješovita populacija stanica osigurava iz tkiva, izborno pri čemu su stanice pužnice ili vestibularni uzorci dobiveni kirurškim intervencijama iz unutrašnjeg uha odraslih.
5. Postupak u skladu sa bilo kojim od prethodnih patentnih zahtjeva, naznačen time što se mješovita populacija stanica dovodi u kontakt sa jednim ili više vezujućih članova aranžiranih tako da se vežu za stanične markere, izborno pri čemu vezujući član sadrži antitijelo, fragment antitijela, ili njegov mimetik.
6. Postupak u skladu sa bilo kojim od prethodnih patentnih zahtjeva, koji sadrži korak detekcije, naznačen time što se stanični markeri detektiraju kao prisutni ili da nisu prisutni na stanici ili grupi stanica, izborno pri čemu detekcija sadrži uporabu FACS i/ili uporabu MACS.
7. Postupak u skladu sa patentnim zahtjevom 5 ili patentnim zahtjevom 6, naznačen time što je vezujući član označen za identifikaciju, izborno pri čemu oznaka sadrži fluoroforu.
8. In vitro postupak identificiranja humanih otičkih progenitorskih stanica u mješovitoj populaciji stanica uporabom najmanje dva markera stanične površine odabrana od SSEA1, GD3, TRA-2-49, SSEA4, GD2 i CD141, postupak sadrži:
- osiguravanje vezujućih članova specifičnih za najmanje dva različita stanična markera;
- dovođenje u kontakt mješovite populacije stanica sa vezujućim članovima; i
- detektiranje vezanja ili nevezanja vezujućih članova za stanice u mješovitoj populaciji stanica.
9. Postupak u skladu sa patentnim zahtjevom 8, naznačen time što postupak dodatno sadrži određivanje da je stanica humana otička progenitorska stanica ukoliko:
a) su vezujući članovi aranžirani tako da se vežu za pozitivne stanične markere vezane za najmanje dva različita pozitivna stanična markera na stanici; ili
b) je vezujući član aranžiran tako da veže jedan od pozitivnih staničnih markera vezan za najmanje jedan od pozitivnih staničnih markera na stanici, i vezujući marker aranžiran da se veže za negativni stanični marker CD141 tako da se ne veže za stanicu,
izborno pri čemu postupak sadrži određivanje da je stanica humana otička progenitorska stanica ukoliko:
i) su vezujući članovi aranžirani tako da se vežu za pozitivne stanične markere vezane za najmanje tri različita pozitivna stanična markera na stanici; ili
ii) su vezujući članovi aranžirani tako da vežu najmanje dva različita pozitivna stanična markera vezana za najmanje dva različita pozitivna stanična markera na stanici, i vezujući marker aranžiran da se veže za negativni stanični marker CD141 tako da se ne veže za stanicu.
10. In vitro postupak obogaćivanja humanih otičkih progenitorskih stanica iz mješovite populacije stanica, postupak sadrži:
- identificiranje humanih otičkih progenitorskih stanica u skladu sa postupkom prema bilo kojem od patentnih zahtjeva 1 do 9; i
- sortiranje stanica tako da se humane otičke progenitorske stanice izoliraju iz ne-otičkih progenitorskih stanica, tako da su humane otičke progenitorske stanice obogaćene u populaciji, izborno pri čemu sortiranje sadrži FACS ili sadrži MACS.
11. In vitro postupak proizvodnje populacije humanih otičkih progenitorskih stanica, postupak sadrži:
- diferenciranje ne-otičkih progenitorskih stanica u humane otičke progenitorske stanice, pri čemu neke ne-otičke progenitorske stanice mogu ostati u populaciji da bi formirale mješovitu populaciju stanica; i
- obogaćivanje humanih otičkih progenitorskih stanica iz mješovite populacije stanica u skladu sa postupkom prema patentnom zahtjevu 10.
12. Komplet koji sadrži najmanje dva različita vezujuća člana, naznačen time što su vezujući članovi aranžirani tako da se vežu za različite stanične markere odabrane od SSEA1, GD3, TRA-2-49, SSEA4, GD2 i CD141, izborno pri čemu komplet sadrži najmanje tri različita vezujuća člana, pri čemu su vezujući članovi aranžirani tako da se vežu za različite stanične markere odabrane od SSEA1, GD3, TRA-2-49, SSEA4, GD2 i CD141.
13. Komplet u skladu sa patentnim zahtjevom 12, naznačen time što komplet sadrži panel vezujućih članova, pri čemu panel vezujućih članova sadrži vezujući član specifičan za svaki od staničnih markera SSEA1, GD3, TRA-2-49, SSEA4, GD2 i CD141.
14. Komplet u skladu sa patentnim zahtjevom 12 ili patentnim zahtjevom 13, naznačen time što su vezujući članovi antitijela, izborno pri čemu su antitijela označena.
15. Uporaba CD141 kao negativnog staničnog markera za identifikaciju humanih ne-otičkih progenitorskih stanica u mješovitoj populaciji stanica.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1615714.1A GB201615714D0 (en) | 2016-09-15 | 2016-09-15 | Otic progenitor identification and isolation |
PCT/GB2017/052707 WO2018051092A1 (en) | 2016-09-15 | 2017-09-14 | Human otic progenitor identification and isolation |
EP17771536.4A EP3513191B1 (en) | 2016-09-15 | 2017-09-14 | Human otic progenitor identification and isolation |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20211049T1 true HRP20211049T1 (hr) | 2021-10-01 |
Family
ID=57288819
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20211049TT HRP20211049T1 (hr) | 2016-09-15 | 2021-06-30 | Identifikacija i izolacija humanog otičkog progenitora |
Country Status (28)
Country | Link |
---|---|
US (2) | US11634687B2 (hr) |
EP (1) | EP3513191B1 (hr) |
JP (1) | JP7134488B2 (hr) |
KR (1) | KR102409178B1 (hr) |
CN (1) | CN109716133B (hr) |
AU (1) | AU2017328903B2 (hr) |
BR (1) | BR112019004749A2 (hr) |
CA (1) | CA3034529A1 (hr) |
CL (1) | CL2019000682A1 (hr) |
CO (1) | CO2019002095A2 (hr) |
CY (1) | CY1124285T1 (hr) |
DK (1) | DK3513191T3 (hr) |
ES (1) | ES2877795T3 (hr) |
GB (1) | GB201615714D0 (hr) |
HR (1) | HRP20211049T1 (hr) |
HU (1) | HUE055453T2 (hr) |
IL (1) | IL265288B2 (hr) |
LT (1) | LT3513191T (hr) |
MA (1) | MA46424B1 (hr) |
MX (1) | MX2019002995A (hr) |
PL (1) | PL3513191T3 (hr) |
PT (1) | PT3513191T (hr) |
RS (1) | RS62083B1 (hr) |
RU (1) | RU2768720C2 (hr) |
SG (1) | SG11201901410SA (hr) |
SI (1) | SI3513191T1 (hr) |
WO (1) | WO2018051092A1 (hr) |
ZA (1) | ZA201902342B (hr) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB201615714D0 (en) * | 2016-09-15 | 2016-11-02 | Univ Of Sheffield The | Otic progenitor identification and isolation |
GB202213060D0 (en) | 2022-09-07 | 2022-10-19 | Rinri Therapeutics Ltd | Surgical method for treatment of auditory disease or condition |
GB202214291D0 (en) | 2022-09-29 | 2022-11-16 | Rinri Therapeutics Ltd | Laminin culture protocol |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2379683A1 (en) | 1999-07-20 | 2001-01-25 | University Of Southern California | Identification of pluripotent pre-mesenchymal, pre-hematopoietic progenitor cell |
US6436704B1 (en) | 2000-04-10 | 2002-08-20 | Raven Biotechnologies, Inc. | Human pancreatic epithelial progenitor cells and methods of isolation and use thereof |
US6534052B1 (en) | 2000-09-05 | 2003-03-18 | Yong-Fu Xiao | Cardiac function comprising implantation of embryonic stem cell in which differentiation has been initiated |
DE60230774D1 (de) | 2001-04-20 | 2009-02-26 | Children S Hospital Of Orange | Isolierung von nervenstammzellen unter verwendung von gangliosiden und anderen oberflächenmarkern |
US8673634B2 (en) | 2003-11-13 | 2014-03-18 | Massachusetts Eye & Ear Infirmary | Method for the treatment of hearing loss |
WO2007117573A2 (en) | 2006-04-07 | 2007-10-18 | Cold Spring Harbor Laboratory | Transgenic mice for identifying and assessing neural stem/ progenitor cells |
WO2008132722A1 (en) * | 2007-04-26 | 2008-11-06 | Ramot At Tel-Aviv University Ltd. | Pluripotent autologous stem cells from oral mucosa and methods of use |
GB2450747A (en) | 2007-07-06 | 2009-01-07 | Univ Sheffield | Treatment of sensorineural hearing loss |
RU2525223C2 (ru) * | 2009-06-08 | 2014-08-10 | Иалоджик Кореа Инк. | Способ стимулирования области волосковых сенсорных клеток |
EP2667881A4 (en) * | 2011-01-24 | 2015-04-22 | Univ Leland Stanford Junior | METHODS OF GENERATING IN VITRO INTERNAL EAR CELLS |
CA2864818C (en) * | 2012-02-17 | 2022-05-03 | The Schepens Eye Research Institute | Phenotype profile of human retinal progenitor cells |
WO2013188679A1 (en) | 2012-06-13 | 2013-12-19 | Stemgent, Inc. | Methods of preparing pluripotent stem cells |
GB201615714D0 (en) * | 2016-09-15 | 2016-11-02 | Univ Of Sheffield The | Otic progenitor identification and isolation |
-
2016
- 2016-09-15 GB GBGB1615714.1A patent/GB201615714D0/en not_active Ceased
-
2017
- 2017-09-14 SI SI201730828T patent/SI3513191T1/sl unknown
- 2017-09-14 MA MA46424A patent/MA46424B1/fr unknown
- 2017-09-14 AU AU2017328903A patent/AU2017328903B2/en active Active
- 2017-09-14 MX MX2019002995A patent/MX2019002995A/es unknown
- 2017-09-14 CN CN201780056911.8A patent/CN109716133B/zh active Active
- 2017-09-14 JP JP2019511989A patent/JP7134488B2/ja active Active
- 2017-09-14 PT PT177715364T patent/PT3513191T/pt unknown
- 2017-09-14 SG SG11201901410SA patent/SG11201901410SA/en unknown
- 2017-09-14 KR KR1020197007122A patent/KR102409178B1/ko active IP Right Grant
- 2017-09-14 US US16/329,935 patent/US11634687B2/en active Active
- 2017-09-14 HU HUE17771536A patent/HUE055453T2/hu unknown
- 2017-09-14 PL PL17771536T patent/PL3513191T3/pl unknown
- 2017-09-14 BR BR112019004749A patent/BR112019004749A2/pt unknown
- 2017-09-14 WO PCT/GB2017/052707 patent/WO2018051092A1/en unknown
- 2017-09-14 RS RS20210826A patent/RS62083B1/sr unknown
- 2017-09-14 LT LTEP17771536.4T patent/LT3513191T/lt unknown
- 2017-09-14 ES ES17771536T patent/ES2877795T3/es active Active
- 2017-09-14 DK DK17771536.4T patent/DK3513191T3/da active
- 2017-09-14 CA CA3034529A patent/CA3034529A1/en active Pending
- 2017-09-14 RU RU2019110990A patent/RU2768720C2/ru active
- 2017-09-14 IL IL265288A patent/IL265288B2/en unknown
- 2017-09-14 EP EP17771536.4A patent/EP3513191B1/en active Active
-
2019
- 2019-03-05 CO CONC2019/0002095A patent/CO2019002095A2/es unknown
- 2019-03-15 CL CL2019000682A patent/CL2019000682A1/es unknown
- 2019-04-12 ZA ZA2019/02342A patent/ZA201902342B/en unknown
-
2021
- 2021-06-30 HR HRP20211049TT patent/HRP20211049T1/hr unknown
- 2021-06-30 CY CY20211100581T patent/CY1124285T1/el unknown
-
2023
- 2023-03-13 US US18/182,829 patent/US20230313134A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20211049T1 (hr) | Identifikacija i izolacija humanog otičkog progenitora | |
Gundry et al. | A cell surfaceome map for immunophenotyping and sorting pluripotent stem cells | |
HRP20201907T1 (hr) | Obogaćivanje cirkulirajućih stanica tumora osiromašenjem bijelih krvnih zrnaca | |
EA200971124A1 (ru) | Множественный анализ образцов крови | |
EA201390638A8 (ru) | Обогащение и идентификация фетальных клеток в материнской крови и лиганды для такого применения | |
WO2015157704A3 (en) | Methods and compositions for detecting misfolded proteins | |
MX2013008471A (es) | Metodos y aparatos para la deteccion de sensibilidad al gluten y su diferenciacion de la enfermedad celiaca. | |
Terrasso et al. | Novel scalable 3D cell based model for in vitro neurotoxicity testing: Combining human differentiated neurospheres with gene expression and functional endpoints | |
US10983123B2 (en) | Markers capable of distinguishing cell pluripotency and uses thereof | |
EP4328587A3 (en) | Use of a kit or device and method for detecting dementia | |
CN202393769U (zh) | 一种梳式斑点酶联免疫多项病毒检测试剂盒 | |
NZ730133A (en) | Test device and method | |
WO2009023331A3 (en) | Antibodies and improved test sample handling methods for use in assays for myeloperoxidase | |
WO2012103337A3 (en) | Assays and methods to sequence microbes directly from immune complexes | |
Coquand et al. | A cell fate decision map reveals abundant direct neurogenesis in the human developing neocortex | |
Ma et al. | Generation and characterization of a human induced pluripotent stem cell (iPSC) line (HEBHMUi001-A) from a sporadic Parkinson's disease patient | |
Janetzki | Elispot for rookies (and experts too) | |
WO2009028202A1 (ja) | 免疫クロマトディバイス | |
Bose et al. | Pluripotent stem cells: Basic biology or else differentiations aimed at translational research and the role of flow cytometry | |
MX2018002411A (es) | Sistemas y metodos para tiras de pruebas sin reactivos. | |
Liu et al. | Spatial transcriptomic profiling to identify mesoderm progenitors with precision genomic screening and functional confirmation | |
DK1644485T3 (da) | Udskilte proteiner som markører for celledifferentiering | |
Reinero et al. | Flow cytometric determination of allergen-specific T lymphocyte proliferation from whole blood in experimentally asthmatic cats | |
Sparks | The Embryotoxic Effects of Harm Reduction Tobacco Products on Osteoblasts Developing from Human Embryonic Stem Cellss | |
CN202216897U (zh) | 一种定量板 |